Seres therapeutics reports inducement grants under nasdaq listing rule 5635(c)(4)

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb) (“seres” or the “company”), a leading microbiome therapeutics company, today announced that on july 31, 2023, the compensation and talent committee of seres' board of directors granted inducement equity grants covering an aggregate of 1950 shares of its common stock to one new employee, consisting of stock options to purchase 975 shares of common stock and restricted stock units (“rsus”), covering 975 shares of its commo.
MCRB Ratings Summary
MCRB Quant Ranking